News
FDA rejects Capricor’s DMD cell therapy, asks for more data
The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising questions about whether the agency's new leadership may be rowing back from some of the flexibility shown by the old regime. Capricor’s share price fell 38% to $7.11 in premarket trading.
Cellular Origins, the Cell and Gene Therapy Catapult, and Resolution Therapeutics have formed a consortium funded by Innovate ...
Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and ...
In an effort to accelerate cell and gene therapy, five New York research centers are teaming up to create the Empire State ...
Pharmaceutical Technology on MSN2d
DoH and Children’s National Hospital link for cell and gene therapyThe DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.
A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to ...
Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...
Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...
The Department of Health - Abu Dhabi (DoH) has signed a strategic Memorandum of Understanding with Children's National ...
Ajay Sood emphasized the need for affordable cell and gene therapies in India, suggesting a national mission to drive down ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback